Natera
NTRA
$220.11
+1.45%
Natera, Inc. is a diagnostic and research company specializing in proprietary molecular and bioinformatics technology for genetic testing and precision medicine. It is a leader in cell-free DNA testing, with key products including the Panorama non-invasive prenatal test (NIPT), the Signatera molecular residual disease (MRD) test for oncology, and the Prospera transplant rejection assessment. The current investor narrative is intensely focused on the company's path to sustainable profitability, following a landmark Q4 2025 where it reported its first quarterly net profit of $47.3 million, sparking a debate on whether this signals a durable inflection point or a one-time anomaly amidst ongoing high-growth investments.…
NTRA
Natera
$220.11
Related headlines
Investment Opinion: Should I buy NTRA Today?
Rating & Thesis: Hold. NTRA presents a compelling but high-risk growth story at a critical inflection point; investors should wait for confirmation of sustainable operating profitability before establishing new positions, despite generally positive analyst sentiment.
Supporting Evidence: The stock trades at a premium trailing PS of 13.6x, which is high but supported by exceptional 39.8% YoY revenue growth. The forward PS of ~5.65x (based on analyst revenue consensus of $5.54B) indicates the market is pricing in significant future growth. The balance sheet is strong (Debt/Equity of 0.125), and Q4 2025 showed positive free cash flow generation. However, core profitability remains unproven, with a negative operating margin of -13.4% and a TTM ROE of -12.2%.
Risks & Conditions: The two biggest risks are 1) the sustainability of profit without tax benefits, and 2) valuation compression if growth decelerates. This Hold rating would upgrade to a Buy if the company reports a second consecutive quarter of positive operating income and maintains revenue growth above 35%. It would downgrade to a Sell if revenue growth decelerates below 25% or if operating losses widen significantly. Currently, the stock appears fairly valued to slightly overvalued relative to its near-term earnings power, but it is priced for long-term growth execution.
Sign up to view all
NTRA 12-Month Price Forecast
NTRA is at a pivotal juncture. The bullish data points—explosive growth and a profit inflection—are powerful but are counterbalanced by concerns over profit quality and extreme valuation. The neutral stance reflects the need for more evidence; specifically, the next 1-2 quarters must show that operating profitability is achievable without large one-time benefits. The high beta suggests the stock will be a leveraged play on this outcome, with high upside if execution continues (bull case to $300) but severe downside to the $130s if it fails. The stance would turn bullish on confirmation of operating profit sustainability and bearish on a growth deceleration below 30%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $286.14 and implied upside of +30.0% versus the current price.
Average Target
$286.14
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$176 - $286
Analyst target range
Analyst coverage for NTRA is limited but generally bullish, with 7 analysts providing estimates. The consensus sentiment leans positive, as evidenced by recent institutional ratings which include actions like 'Overweight' from Morgan Stanley and 'Outperform' from Baird and Evercore ISI, with only Wells Fargo maintaining an 'Equal Weight'. Specific consensus price targets and implied upside are not provided in the dataset, preventing a calculation of the average target and spread. The range of analyst estimates for future performance shows an EPS range of $4.66 to $5.06 and a revenue range of $5.34B to $5.68B for the estimated period, indicating a relatively tight band of expectations and moderate conviction in the forward outlook. The recent news of a high-profile investor like Stanley Druckenmiller taking a position may further bolster institutional interest. The absence of a broad price target range in the data suggests that while analyst sentiment is tracked, precise price expectations are less defined, which is common for growth companies with high uncertainty around future profit streams.
Bulls vs Bears: NTRA Investment Factors
The bull case, centered on a definitive profitability inflection and sustained 40% revenue growth, currently holds stronger evidence based on the concrete Q4 2025 results. However, the bear case presents a formidable counter-argument focused on the quality and sustainability of that profit, given its reliance on a large tax benefit. The single most important tension in the investment debate is whether the Q4 profit marks the beginning of durable, operating-driven profitability that justifies its premium sales multiple, or if it proves to be a one-time accounting anomaly that leaves the stock overvalued relative to its still-negative core earnings. The resolution of this tension, observable in upcoming quarterly operating income figures, will dictate the stock's direction.
Bullish
- First Quarterly Profit Inflection: Q4 2025 delivered a landmark net income of $47.3 million, a net margin of 7.1%, and positive free cash flow of $37.8 million. This swing from consistent losses signals a potential durable shift toward sustainable profitability, driven by robust revenue growth and expanding gross margins.
- Exceptional Revenue Growth Trajectory: Revenue grew 39.8% YoY in Q4 2025 to $665.5 million, continuing a hyper-growth trend. Analyst consensus projects forward revenue of ~$5.54 billion, implying a forward Price-to-Sales ratio of approximately 5.65x, which is a significant discount to the trailing PS of 13.6x, pricing in continued high growth.
- The company has a robust financial position with a current ratio of 3.39 and a low debt-to-equity ratio of 0.125. This provides ample internal funding for growth investments without reliance on dilutive financing, as evidenced by the positive TTM free cash flow of $96.6 million.
- Improving Gross Margin Trend: Gross margin expanded to 67.1% in Q4 2025, up from 63.2% in Q1 2025. This consistent improvement demonstrates pricing power and operating leverage as the company scales its high-margin oncology (Signatera) and transplant (Prospera) testing franchises.
Bearish
- Profitability Reliant on Tax Benefit: The Q4 2025 net profit of $47.3 million was significantly aided by a $60.6 million income tax benefit. Excluding this, operating income was negative $22.8 million, raising questions about the sustainability of core earnings power without one-time items.
- Extreme Volatility & High Beta: With a beta of 1.54, NTRA is over 50% more volatile than the market, contributing to sharp price swings like the recent correction from its 52-week high of $256.36. This high volatility makes it a risky holding for risk-averse investors and complicates entry/exit timing.
- Premium Valuation Despite Losses: The stock trades at a trailing PS ratio of 13.6x and an EV/Sales of 12.2x, which is high for the diagnostics sector. The trailing P/E is deeply negative at -150.5, and the PEG ratio is an extreme 230.2, indicating the market is pricing in near-perfect execution of future growth.
- Sequential Growth Deceleration Risk: While YoY growth remains strong at ~40%, the sequential acceleration from prior hyper-growth phases may be normalizing. Any miss against the high forward revenue estimate of $5.54B could trigger multiple compression given the premium valuation.
NTRA Technical Analysis
The stock is in a volatile, range-bound consolidation phase following a significant correction from its highs. Over the past year, NTRA has gained 29.04%, but this masks a sharp pullback; the current price of $212.07 sits at approximately 64% of its 52-week range ($131.81 to $256.36), indicating it is trading closer to the midpoint after a substantial retreat from the highs, suggesting a cooling of prior momentum. Recent momentum shows signs of stabilization, with a 12.89% gain over the past three months and an 8.58% gain over the past month, which contrasts with the negative 6-month and year-to-date performance of -8.57% and -7.33%, respectively. This divergence suggests the stock may be attempting to establish a base after its February-March 2026 decline, though the high beta of 1.54 indicates it remains over 50% more volatile than the broader market, contributing to its sharp swings. Key technical support is anchored at the 52-week low of $131.81, while immediate overhead resistance is at the recent high near $256.36. A sustained breakout above this resistance would signal a resumption of the primary uptrend, while a breakdown below the $190-$200 area (recent lows from March-April 2026) could retest the 52-week low. The elevated beta underscores the stock's high-risk, high-reward profile, necessitating careful position sizing.
Beta
1.54
1.54x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$132-$256
Price range past year
Annual Return
+30.8%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | +18.1% | +1.5% |
| 3m | +11.3% | +13.4% |
| 6m | -2.1% | +10.9% |
| 1y | +30.8% | +24.5% |
| ytd | -3.8% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Revenue growth remains exceptionally strong but shows signs of sequential deceleration from peak rates. Q4 2025 revenue reached $665.5 million, representing a robust 39.8% year-over-year growth; however, this follows quarters of even higher growth earlier in 2025 (e.g., Q3 revenue of $592.2 million grew 34.7% YoY). The product segment, at $661.2 million in Q4, is the overwhelming driver, while licensing contributes a minimal $4.3 million. The trajectory implies the core business is scaling rapidly, though the pace may be normalizing from hyper-growth levels. Profitability has reached a critical inflection point, with Q4 2025 delivering a net income of $47.3 million (net margin of 7.1%) and a gross margin of 67.1%. This contrasts sharply with the net losses and lower gross margins in prior quarters of 2025 (Q3 net loss of -$87.5 million, gross margin 64.9%). The swing to profitability was aided by a significant income tax benefit of -$60.6 million; excluding this, operating income was still negative at -$22.8 million. The trend shows improving gross margins (up from 63.2% in Q1 2025) and narrowing operating losses, signaling progress toward sustainable earnings. The balance sheet is healthy with strong liquidity, evidenced by a current ratio of 3.39 and a low debt-to-equity ratio of 0.125. The company generated positive free cash flow of $96.6 million on a TTM basis and $37.8 million in Q4 alone. With an ROE of -12.2% (TTM) but a positive ROA of -9.1%, the financial health is solid, providing ample internal funding for growth without reliance on excessive debt, though shareholder returns remain negative due to cumulative losses.
Quarterly Revenue
$665500000.0B
2025-12
Revenue YoY Growth
+0.39%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$96613000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Given the company's inconsistent profitability, with a trailing twelve-month net income marginally negative at -$0.0066 per share, we lead with the Price-to-Sales (PS) ratio as the primary valuation metric. NTRA trades at a trailing PS ratio of 13.58x and an EV/Sales of 12.22x. The forward PS ratio is not explicitly provided, but analyst revenue estimates for the next period average $5.54 billion, implying a forward PS of approximately 5.65x based on the current market cap, indicating the market expects significant sales growth to justify the current multiple. Compared to industry averages, data is not available in the provided dataset for a direct sector PS comparison. However, a PS of 13.6x is typically high for a diagnostics company, suggesting the market is pricing in premium growth expectations, particularly for its oncology (Signatera) and transplant (Prospera) franchises. Historically, NTRA's own valuation has compressed significantly from extreme levels; its current PS of 13.6x is far below its historical peak of over 70x seen in mid-2021 and is near the lower end of its multi-year range. This suggests the stock is no longer priced for perfection, but rather for a more realistic growth scenario with a path to profitability, potentially offering a more balanced risk/reward profile if execution continues.
PE
-150.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -124x~166x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-138.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the sustainability of profitability. While Q4 2025 showed a net profit, it was heavily supported by a $60.6 million tax benefit; core operating income remained negative at -$22.8 million. The company's valuation (13.6x PS) is entirely predicated on continued hyper-growth (39.8% YoY) to eventually justify the multiple. A deceleration in revenue growth or a reversal in the improving gross margin trend (currently 67.1%) would severely pressure the stock, as the TTM net margin is still negative at -9.0%.
Market & Competitive Risks: NTRA faces significant valuation compression risk. Trading at a trailing PS of 13.6x—historically high for diagnostics—it is vulnerable to sector-wide de-rating if interest rates remain elevated, compressing growth stock multiples. Its high beta of 1.54 makes it acutely sensitive to broader market pullbacks, as seen in its 6-month underperformance of -8.6% vs. the SPY's +8.8% gain. Competitive and regulatory risks in the rapidly evolving liquid biopsy and MRD testing space could also threaten its growth premium and market leadership in Signatera and Prospera.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth slowdown (e.g., revenue growth falling below 30%), a failure to achieve sustainable operating profitability in subsequent quarters, and a broad market sell-off impacting high-beta names. This could trigger a re-rating toward its 52-week low of $131.81, representing a downside of approximately -38% from the current price of $212.07. The stock's history of a -28.2% max drawdown and its recent volatile trading pattern support the plausibility of such a sharp decline if execution falters.
FAQ
The key risks are: 1) Profitability Sustainability Risk: The Q4 net profit was heavily aided by a $60.6 million tax benefit; core operations are not yet consistently profitable (operating margin -13.4%). 2) Valuation & Volatility Risk: The high PS ratio of 13.6x and beta of 1.54 make the stock vulnerable to sharp declines if growth disappoints or the market corrects. 3) Execution & Competitive Risk: The company must continue to execute hyper-growth (near 40%) in its Signatera and Prospera franchises while fending off competition in the rapidly evolving liquid biopsy space. 4) Reimbursement Risk: Widespread adoption depends on favorable coverage decisions from insurers and government payers.
Our 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $200 and $240 as it consolidates, awaiting clearer profit trends. The Bull Case (30% probability), driven by sustained operating profitability and growth, targets $256 to $300. The Bear Case (20% probability), triggered by growth deceleration and profit disappointment, sees a drop to $132-$180. The most likely outcome is the Base Case, which assumes the company meets analyst revenue estimates of ~$5.54B but continues to exhibit volatile quarterly earnings as it invests for growth.
NTRA appears fairly valued to slightly overvalued based on near-term fundamentals but could be undervalued if its long-term growth trajectory is fully realized. The trailing Price-to-Sales ratio of 13.6x is high for the diagnostics sector and reflects premium growth expectations (39.8% YoY). However, the forward PS of approximately 5.65x (based on analyst revenue consensus) suggests the market is already discounting massive future sales growth. Given the company's still-negative core operating margins, the current valuation implies the market expects flawless execution and a rapid transition to sustained profitability.
NTRA is a speculative buy for aggressive, risk-tolerant investors who believe in its long-term market leadership and can stomach high volatility (beta 1.54). The recent Q4 profit of $47.3 million is a positive signal, but its reliance on a tax benefit means sustainable profitability is not yet proven. With a premium valuation (13.6x PS) pricing in near-perfect execution, it carries significant downside risk (potentially -38% to its 52-week low). For most investors, it is prudent to wait for a second quarter of confirmed operating profitability before considering a position.
NTRA is unequivocally a long-term investment, requiring a minimum horizon of 3-5 years to allow its growth narrative and path to sustainable profitability to fully play out. Its high beta of 1.54 and lack of dividend make it a poor choice for short-term trading or income-seeking investors. The stock's extreme volatility can lead to significant short-term drawdowns (e.g., -28.2% max drawdown), which long-term investors must be prepared to endure. Only investors with conviction in the company's multi-year market expansion in oncology and transplant testing should consider holding NTRA.
